Income Statement
DESIGN THERAPEUTICS, INC.
DSGN
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
79.47 | 62.38 | 78.19 | 67.59 | 35.83 |
|
Research & Development
|
59.13 | 44.35 | 57.06 | 48.61 | 24.78 |
|
Selling, General & Administrative
|
20.34 | 18.03 | 21.13 | 18.98 | 11.05 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-79.47 | -62.38 | -78.19 | -67.59 | -35.83 |
|
Non-Operating Income
|
- | - | - | - | - |
|
Interest Income
|
9.68 | 12.80 | - | - | - |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | 11.33 | 4.29 | 0.30 |
|
Income Before Tax
|
- | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-69.79 | -49.59 | -66.86 | -63.31 | -35.53 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-79.47 | -62.38 | -78.19 | -67.59 | -35.83 |
|
Earnings Per Share (Basic)
|
-1.22 | -0.88 | -1.19 | -1.14 | - |
|
Diluted EPS
|
-1.22 | -0.88 | -1.19 | -1.14 | - |
|
Weighted Average Shares
|
57.33 | 56.59 | 55.98 | 55.71 | - |
|
Diluted Weighted Avg Shares
|
57.33 | 56.59 | 55.98 | 55.71 | - |
|
Comprehensive Income
|
-69.86 | -49.18 | -63.44 | -66.42 | -35.93 |